Please note: The information displayed on this page might be outdated.
Oncimmune: Oncimmune's proprietary platform is underpinned by rapid biomarker discovery and a comprehensive immunogenic protein library of over 8,000 antigenic proteins. Oncimmune has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making. Oncimmune's patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.
Based in...
Europe, United Kingdom
Disease Space
Diagnostics, Immuno-Oncology, Oncology
Europe, Public
Market Cap
Clinical Sciences Building, City Hospital, Hucknall Road
Nottingham, NG5 1PB
United Kingdom

Company Participants at European Biotech Investor Day 2019

  • Adam Hill, Dr, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Oncimmune Holdings Plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Ruffer LLP 4.74 3,000,000 5.16 Stakes 2020-05-29
Miton Asset Management Ltd. 2.92 1,845,457 3.17 Funds 2020-03-31
Gabelli Funds LLC 0.01 4,000 0.01 Funds 2019-12-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.